Global UAV Announces Business Combination Transaction with Nexus Peptide Sciences Inc

Global UAV Technologies Ltd. (CSE: UAV) (OTC Pink: YRLLF) (FSE: YAB) is pleased to announce that it is has entered into a definitive amalgamation agreement (the " Amalgamation Agreement ") with Nexus Peptide Sciences Inc. (" Nexus "), a private corporation existing under the laws of British Columbia, dated August 24, 2026, and 1604759 B.C. Ltd. (" Newco ") a private corporation existing under the laws of British Columbia, pursuant to which the Company would complete a business combination with Nexus and acquire all of the outstanding securities of Nexus from the securityholders of Nexus by way of "three-cornered" amalgamation (the " Transaction ").

About Nexus Peptide Sciences Inc. Nexus is a private biotechnology company, based in Vancouver, British Columbia. Nexus is developing peptide formulations and delivery systems intended to improve stability, absorption and practical use across metabolic health, recovery and longevity applications. Peptides are short chains of amino acids that act as native signalling molecules, regulating metabolism, repair, immunity and cognition. Nexus' platform is directed at what the company identifies as the principal constraint on peptide adoption —the molecule itself and the route of delivery, as most peptides degrade rapidly, struggle to cross biological barriers and require injection to remain stable. Nexus' work spans five areas: molecular optimization (sequence and structural refinement to improve stability, half-life and target selectivity); formulation chemistry (excipient and carrier systems engineered for solubility, shelf-stability and consistent dosing); researching optimal delivery systems (needle-free formats including transdermal patches, oral platforms and absorption-enhanced carriers); quality and verification (manufacturing in approved facilities with batch-level third-party analytical testing for identity, purity and contamination); and regulatory alignment (monitoring of U.S. and international policy to align product positioning with the evolving framework for peptide-based products).

Currently, Nexus has designed a series of D-peptide analogues derived from six bioactive peptide leads. These analogues are currently being prepared, with pharmacokinetic studies planned to identify candidates with improved stability and drug-like properties. Freedom-to-operate analysis is underway, and Nexus has a plan in place, based on expert advice, for the development of intellectual property (" IP "). Once Nexus has completed the development and assessment of the potential IP, any necessary patents will then be filed.

Further information regarding Nexus, its business, its programs and its financial position will be included in the listing statement to be prepared in connection with the Transaction and filed under the Company's profile on SEDAR+.

Summary of the Transaction Pursuant to the terms of the Amalgamation Agreement, the Company has agreed to acquire all of the issued and outstanding common shares (each, a " Nexus Share ") of Nexus by way of "three-cornered" amalgamation whereby Newco and Nexus will amalgamate to form a new entity (" Amalco "), and Amalco will be a wholly-owned subsidiary of the Company upon completion of the Transaction (the " Closing "). At the effective time of the Closing, each of the outstanding Nexus Shares will be cancelled and, in consideration for such Nexus Shares, each respective Nexus shareholder will receive their pro rata portion of an aggregate of 20,500,000 common shares (each, a " Share ") in the capital of the Company and 7,000,000 transferable share purchase warrants (each, a " Warrant ") of the Company. Each Warrant is exercisable into one (1) additional Share (each, a " Warrant Share ") at an exercise price of $0.10 per Warrant Share for a period of two (2) years following the Closing. The Company and Nexus negotiated at arm's length and no valuations were ...